Wild-type p53 activates transcription in vitro
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The p53 protein is an important determinant in human cancer and regulates the growth of cells in culture. It is known to be a sequence-specific DNA-binding protein with a powerful activation domain, but it has not been established whether it regulates transcription directly. Here we show that intact purified wild-type human and murine p53 proteins strongly activate transcription in vitro. This activation depends on the ability of p53 to bind to a template bearing a p53-binding sequence. By contrast, tumour-derived mutant p53 proteins cannot activate transcription from the template at all, and when complexed to wild-type p53, these mutants block transcriptional activation by the wild-type protein. Moreover, the simian virus 40 large T antigen inhibits wild-type p53 from activating transcription. Our results support a model in which p53 directly activates transcription but this activity can be inhibited by mutant p53 and SV40 large T antigen through interaction with wild-type p53.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The tumor-suppressor protein, p53, plays a central role in the cellular response to UV-induced DNA damage/repair (13).”
From Melanocyte-stimulating hormone directly enhances UV-Induced DNA repair in keratinocytes by a xeroderma pigmentosum group A-dependent mechanism (2010) · cites this paper as [13]
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
How eukaryotic transcriptional activators work
Ptashne, M. (1988) · Nature · doi:10.1038/335683a0 · Cited by 1,825
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
p53: oncogene or anti-oncogene?
Lane, D. P., & Benchimol, S. (1990) · Genes & Development · doi:10.1101/gad.4.1.1 · Cited by 795
Presence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
Gannon, J. V., Greaves, R., Iggo, R., & Lane, D. P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08279.x · Cited by 688
Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene
Raycroft, L., Wu, H., & Lozano, G. (1990) · Science · doi:10.1126/science.2144364 · Cited by 619
Research works printed but not linked: 7
- O'Rourke, R. W. et al. Oncogene 5, 1829–1832 (1990).
- Zhu, H., Roy, A. L., Roeder, R. G. & Prywes, R. New Biologist 3, 455–464 (1991).
- Kern, S. E. et al. Oncogene 6, 131–136 (1991).
- Fried, M. & Prives, C. Cancer Cells 4, 1–16 (1986).
- Soussi, T., Caron de Fromentel, C. & May, P. Oncogene 5, 945–952 (1990).
- Murakami, Y., Asano, M., Satake, M. & Ito, Y. Oncogene 5, 5–14 (1990).
- Zambetti, G. P. et al. Genes Dev. (in the press).
Cited by
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
“In addition, wild-type ~53 can directly activate transcription in vitro (Farmer et al., 1992).”
Backgroundp53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Self-citationTumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
“Through these and many subsequent studies (for example Ref”
Vogelstein, B. (1992) · Cell · doi:10.1016/0092-8674(92)90421-8 · Cited by 1,862
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
“…oncogene products of several DNA tumor viruses bind to the p53 protein (Lane and Crawford 1979; Linzer and Levine 1979; Sarnow et al. 1982; Werness et al. 1990) and block its ability to function as a transcription factor (Farmer et al. 1992; Kern et al. 1992; Mietz et al. 1992; Yew and Berk 1992).”
BackgroundMethodDulić, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Lees, E., Harper, J. W., Elledge, S. J., & Reed, S. I. (1994) · Cell · doi:10.1016/0092-8674(94)90379-4 · Cited by 1,465
mdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Regulation of the specific DNA binding function of p53
Hupp, T. R., Meek, D. W., Midgley, C. A., & Lane, D. P. (1992) · Cell · doi:10.1016/0092-8674(92)90562-q · Cited by 909
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B.
Debbas, M., & White, E. (1993) · Genes & Development · doi:10.1101/gad.7.4.546 · Cited by 871
Abnormal Centrosome Amplification in the Absence of p53
Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S., & Woude, G. F. V. (1996) · Science · doi:10.1126/science.271.5256.1744 · Cited by 797
Massova, I., & Kollman, P. A. (1999) · Journal of the American Chemical Society · doi:10.1021/ja990935j · Cited by 780
Roulston, A., Marcellus, R. C., & Branton, P. E. (1999) · Annual Review of Microbiology · doi:10.1146/annurev.micro.53.1.577 · Cited by 749
Wild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression
Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W.-W., Kruzel, E., et al. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3032 · Cited by 734
Mapping of the p53 and mdm-2 interaction domains.
Chen, J., Marechal, V, & Levine, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4107 · Cited by 689
“p53 has been shown to be a DNA binding protein with the ability to activate transcription through binding to specific DNA sequences adjacent to promoters (7, 17, 19, 50).”
BackgroundCentral role of p53 in the suntan response and pathologic hyperpigmentation
Cui, R., Widlund, H. R., Feige, E., Lin, J. Y., Wilensky, D. L., Igras, V. E., D'Orazio, J., Fung, C. Y., Schanbacher, C. F., Granter, S. R., et al. (2007) · Cell · doi:10.1016/j.cell.2006.12.045 · Cited by 657
“The tumor-suppressor protein p53 (Lane and Crawford, 1979; Linzer and Levine, 1979) is a transcription factor that plays a pivotal role in the cellular response to genotoxic stressors such as UV and chemically induced DNA damage (Fields and Jang, 1990; Farmer et al., 1992).”
Lin, J., Chen, J., Elenbaas, B., & Levine, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.10.1235 · Cited by 653
Analysis of p53-regulated gene expression patterns using oligonucleotide arrays
Zhao, R., Gish, K., Murphy, M., Yin, Y., Notterman, D., Hoffman, W. H., Tom, E., Mack, D. H., & Levine, A. J. (2000) · Genes & Development · doi:10.1101/gad.14.8.981 · Cited by 634
“Wild-type p53 is a sequence-specific transcriptional activator (Fields and Jang 1990; Raycroft et al. 1990; Farmer et al. 1992).”
Structure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2
Gorina, S., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.1001 · Cited by 571
p53 mutations increase resistance to ionizing radiation.
Lee, J. M., & Bernstein, A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5742 · Cited by 564
Huibregtse, J. M., Scheffner, M., & Howley, P. M. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.2.775 · Cited by 233
Crystal Structure of the Tetramerization Domain of the p53 Tumor Suppressor at 1.7 Angstroms
Jeffrey, P. D., Gorina, S., & Pavletich, N. P. (1995) · Science · doi:10.1126/science.7878469 · Cited by 549
Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.
Harvey, M., McArthur, M. J., Montgomery, C. A., Butel, J. S., Bradley, A., & Donehower, L. A. (1993) · Nature Genetics · doi:10.1038/ng1193-225 · Cited by 542
Malkin, D. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 508
Wild-type p53 binds to the TATA-binding protein and represses transcription.
Seto, E., Usheva, A., Zambetti, G. P., Momand, J., Horikoshi, N., Weinmann, R., Levine, A. J., & Shenk, T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12028 · Cited by 504
Characterization of the p53-Dependent Postmitotic Checkpoint following Spindle Disruption
Lanni, J. S., & Jacks, T. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.1055 · Cited by 497
“Functional analysis of the p53 protein has shown that it is a transcription factor with sequence-specific DNA binding activity (12, 22, 42).”
BackgroundP53, cell cycle control and apoptosis: Implications for cancer
Kastan, M. B., Canman, C. E., & Leonard, C. J. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00690207 · Cited by 482
p53 in growth control and neoplasia
Gottlieb, T. M., & Oren, M. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00019-c · Cited by 481
Identification of redox/repair protein Ref-1 as a potent activator of p53.
Jayaraman, L., Murthy, K. G., Zhu, C., Curran, T., Xanthoudakis, S., & Prives, C. (1997) · Genes & Development · doi:10.1101/gad.11.5.558 · Cited by 481
p53 Research: The Past Thirty Years and the Next Thirty Years
Lane, D., & Levine, A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000893 · Cited by 454
Mechanisms of transcriptional regulation by p53
Sullivan, K. D., Galbraith, M. D., Andrysik, Z., & Espinosa, J. M. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.174 · Cited by 446
p53 Transcriptional Activation Mediated by Coactivators TAF II 40 and TAF II 60
Thut, C. J., Chen, J.-L., Klemm, R., & Tjian, R. (1995) · Science · doi:10.1126/science.7809597 · Cited by 439
p53 regulates a G 2 checkpoint through cyclin B1
Innocente, S. A., Abrahamson, J. L. A., Cogswell, J. P., & Lee, J. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2147 · Cited by 436
The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis
Levine, A., Perry, M., Chang, A., Silver, A., Dittmer, D., Wu, M., & Welsh, D. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.76 · Cited by 422
p53-Dependent apoptosis pathways
(2001) · Advances in Cancer Research · doi:10.1016/s0065-230x(01)82002-9 · Cited by 418
p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells
Di Como, C. J., Gaiddon, C., & Prives, C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417
“5A and E), as previously described (13, 17, 35); reviewed in reference 69).”
BackgroundMethodA comparison of the biological activities of wild‐type and mutant p53
Zambetti, G. P., & Levine, A. J. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344485 · Cited by 413
“Purified human and murine wild-type p53 protein can in fact strongly transactivate transcription from a minimal human fos promoter that contains a single 33 bp RGC p53 DNA binding element upstream from the TATA element in an in vitro transcription assay using partially purified HeLa cell nuclear extracts (78).”
BackgroundMethodDNA Copy Number Losses in Human Neoplasms
Knuutila, S., Aalto, Y., Autio, K., Björkqvist, A.-M., El-Rifai, W., Hemmer, S., Huhta, T., Kettunen, E., Kiuru-Kuhlefelt, S., Larramendy, M. L., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65166-8 · Cited by 397
“It codes for a protein, p53, that acts as a transcription factor and prevents damaged DNA from replicating.(151,152) Losses or other inactivating mutations in TP53 are possibly the most common genetic DNA Copy Number Losses in Human Neoplasms 687 AJP September 1999, Vol.”
BackgroundHuibregtse, J. M., Scheffner, M., & Howley, P. M. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.8.4918 · Cited by 182
Role of Stat3 in Regulating p53 Expression and Function
Niu, G., Wright, K. L., Ma, Y., Wright, G. M., Huang, M., Irby, R., Briggs, J., Karras, J., Cress, W. D., Pardoll, D., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7432-7440.2005 · Cited by 392
“Indeed, it has been shown that the oncogenic potential of simian virus 40 (SV40) large T antigen depends on its ability to negatively regulate p53 activity, providing a mechanism by which oncoproteins inhibit p53 function in the absence of p53 mutations (3, 16, 34, 38).”
BackgroundWerner, H., Karnieli, E., Rauscher, F. J., & LeRoith, D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8318 · Cited by 370
Cellular transformation by SV40 large T antigen: interaction with host proteins
Ali, S. H., & DeCaprio, J. A. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0342 · Cited by 367
Mietz, J. A., Unger, T., Huibregtse, J. M., & Howley, P. M. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05608.x · Cited by 365
Molecular Genetics of Acute Lymphoblastic Leukemia
Armstrong, S. A., & Look, A. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.047 · Cited by 362
p53-mediated cell death: relationship to cell cycle control.
Yonish-Rouach, E., Grunwald, D., Wilder, S., Kimchi, A., May, E., Lawrence, J. J., May, P., & Oren, M. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.3.1415 · Cited by 344
Shaulian, E., Zauberman, A., Ginsberg, D., & Oren, M. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5581 · Cited by 342
Donehower, L. A., & Bradley, A. (1993) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(93)90004-v · Cited by 333
Pancreatic adenocarcinomas frequently show p53 gene mutations.
Scarpa, A., Capelli, P., Mukai, K., Zamboni, G., Oda, T., Iacono, C., & Hirohashi, S. (1993) · PubMed · Cited by 332
Bax Involvement in p53-Mediated Neuronal Cell Death
Xiang, H., Kinoshita, Y., Knudson, C. M., Korsmeyer, S. J., Schwartzkroin, P. A., & Morrison, R. S. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-04-01363.1998 · Cited by 330
“The p53 protein functions as a site-specific transactivator of transcription (Kern et al., 1991; Farmer et al., 1992; Zambetti et al., 1992) and has been shown to activate the proapoptotic gene, Bax (Miyashita et al., 1994; Miyashita and Reed, 1995).”
BackgroundBarak, Y., Gottlieb, E., Juven-Gershon, T., & Oren, M. (1994) · Genes & Development · doi:10.1101/gad.8.15.1739 · Cited by 328
Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53
Mack, D. H., Vartikar, J., Pipas, J. M., & Laimins, L. A. (1993) · Nature · doi:10.1038/363281a0 · Cited by 322
Zambetti, G. P., Bargonetti, J., Walker, K., Prives, C., & Levine, A. J. (1992) · Genes & Development · doi:10.1101/gad.6.7.1143 · Cited by 311
Increased activity of p53 in senescing fibroblasts
Atadja, P., Wong, H., Garkavtsev, I., Veillette, C., & Riabowol, K. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.18.8348 · Cited by 308
Role of Cysteine Residues in Regulation of p53 Function
Rainwater, R., Parks, D., Anderson, M. E., Tegtmeyer, P., & Mann, K. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.7.3892 · Cited by 306
“Wild-type p53 is thought to suppress tumor formation by acting as a transcriptional regulator (13, 31, 46).”
BackgroundVan Meir, E. G., Polverini, P. J., Chazin, V. R., Su Huang, H.-J., de Tribolet, N., & Cavenee, W. K. (1994) · Nature Genetics · doi:10.1038/ng1094-171 · Cited by 307
The molecular basis for cell cycle delays following ionizing radiation: a review
Maity, A., McKenna, W. G., & Muschel, R. J. (1994) · Radiotherapy and Oncology · doi:10.1016/0167-8140(94)90408-1 · Cited by 294
Inhibition of RNA polymerase II as a trigger for the p53 response
Ljungman, M., Zhang, F., Chen, F., Rainbow, A. J., & McKay, B. C. (1999) · Oncogene · doi:10.1038/sj.onc.1202356 · Cited by 288
“The active form of the p53 protein binds DNA as a tetramer in a sequencedependent manner and transactivates target genes (Farmer et al., 1992; Zambetti et al., 1992) while concurrently reducing transcription of other genes (Ginsberg et al., 1991).”
BackgroundHarris, C. C. (1996) · Carcinogenesis · doi:10.1093/carcin/17.6.1187 · Cited by 285
Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53.
Yew, P. R., Liu, X., & Berk, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.2.190 · Cited by 283
Donehower, L. A., Godley, L. A., Aldaz, C. M., Pyle, R., Shi, Y. P., Pinkel, D., Gray, J., Bradley, A., Medina, D., & Varmus, H. E. (1995) · Genes & Development · doi:10.1101/gad.9.7.882 · Cited by 276
Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53
Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Zeslawski, W., Kamionka, M., Rehm, T., Mühlhahn, P., et al. (2001) · Biochemistry · doi:10.1021/bi000930v · Cited by 275
Repression of p53-mediated transcription by MDM2: a dual mechanism
Thut, C. J., Goodrich, J. A., & Tjian, R. (1997) · Genes & Development · doi:10.1101/gad.11.15.1974 · Cited by 272
“…induce a G1 arrest is dependent on its ability to function as a site-specific transcriptional activator (Fields and Jang 1990; Raycroft et al. 1990; Farmer et al. 1992; Kern et al. 1992; Unger et al. 1992; Zambetti et al. 1992; Attardi et al. 1996) and to induce the expression of genes whose…”
BackgroundGomes, N. P., Bjerke, G., Llorente, B., Szostek, S. A., Emerson, B. M., & Espinosa, J. M. (2006) · Genes & Development · doi:10.1101/gad.1398206 · Cited by 266
“…during tumor growth, and as a result p53 is the most commonly mutated tumor suppressor gene (Vogelstein et al. 2000; Vousden 2002). p53 is a sequence-specific DNA-binding protein that functions primarily as a transcriptional regulator (Kern et al. 1991; Farmer et al. 1992; Zhao et al. 2000).”
BackgroundPolo-like Kinase 1 (Plk1) Inhibits p53 Function by Physical Interaction and Phosphorylation
Ando, K., Ozaki, T., Yamamoto, H., Furuya, K., Hosoda, M., Hayashi, S., Fukuzawa, M., & Nakagawara, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314182200 · Cited by 264
The p53 protein is an unusually shaped tetramer that binds directly to DNA.
Friedman, P. N., Chen, X., Bargonetti, J., & Prives, C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3319 · Cited by 264
Liu, X., Miller, C. W., Koeffler, P. H., & Berk, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.6.3291 · Cited by 260
“Previous experiments have shown that p53 binds to DNA and activates transcription both in vivo and in vitro (9, 10, 22).”
p53 induction is associated with neuronal damage in the central nervous system.
Sakhi, S., Bruce, A., Sun, N., Tocco, G., Baudry, M., & Schreiber, S. S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7525 · Cited by 259
Milne, D. M., Campbell, L. E., Campbell, D. G., & Meek, D. W. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.10.5511 · Cited by 257
Truant, R., Antunovic, J., Greenblatt, J., Prives, C., & Cromlish, J. A. (1995) · Journal of Virology · doi:10.1128/jvi.69.3.1851-1859.1995 · Cited by 255
“GAL4(1-96):p53(1-73), expressed in BL21(DE3) (65), was extracted from the insoluble 10,000 3 g pellet prepared from a sonicated resuspended bacterial pellet (resuspended pellet from 1 liter of bacteria in 80 ml of 20 mM HEPES [N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid], pH 7.”
MethodInfluentialFries, K. L., Miller, W. E., & Raab-Traub, N. (1996) · Journal of Virology · doi:10.1128/jvi.70.12.8653-8659.1996 · Cited by 255
“The p53 protein can also be inactivated by viral oncogenes including simian virus 40 T antigen (19, 20, 36, 50), adenovirus E1B 55K (19, 81), and human papillomavirus E6 (50, 68, 78).”
BackgroundApoptosis induced by inhibition of intercellular contact.
Bates, R. C., Buret, A., van Helden, D. F., Horton, M. A., & Burns, G. F. (1994) · The Journal of cell biology · doi:10.1083/jcb.125.2.403 · Cited by 248
“It is well established that the wild-type p53 binds strongly to double stranded DNA and can activate transcription (Farmer et al., 1992) hence movement to the nucleus is paramount for the protein to exert its profound biological effects.”
BackgroundGarcía-Echeverría, C., Chène, P., Blommers, M. J. J., & Furet, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990966p · Cited by 246
Screening patients for heterozygous p53 mutations using a functional assay in yeast
Ishioka, C., Frebourg, T., Yan, Y.-X., Vidal, M., Friend, S. H., Schmidt, S., & Iggo, R. (1993) · Nature Genetics · doi:10.1038/ng1093-124 · Cited by 243
p53 domains: identification and characterization of two autonomous DNA-binding regions.
Wang, Y., Reed, M., Wang, P., Stenger, J. E., Mayr, G., Anderson, M. E., Schwedes, J. F., & Tegtmeyer, P. (1993) · Genes & Development · doi:10.1101/gad.7.12b.2575 · Cited by 239
Zhang, Q., Gutsch, D., & Kenney, S. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1929 · Cited by 237
Lee, D., Kim, J. W., Seo, T., Hwang, S. G., Choi, E.-J., & Choe, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111987200 · Cited by 232
Glucose Catabolism in Cancer Cells
Mathupala, S. P., Heese, C., & Pedersen, P. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22776 · Cited by 231
Glucose Catabolism in Cancer Cells.
Mathupala, S. P., Rempel, A., & Pedersen, P. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16918 · Cited by 229
Inhibition of p53 DNA binding by human papillomavirus E6 proteins
Lechner, M. S., & Laimins, L. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.7.4262-4273.1994 · Cited by 195
Cell type-specific inhibition of p53-mediated apoptosis by mdm2.
Haupt, Y., Barak, Y., & Oren, M. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00504.x · Cited by 228
Harvey, M., Vogel, H., Morris, D., Bradley, A., Bernstein, A., & Donehower, L. A. (1995) · Nature Genetics · doi:10.1038/ng0395-305 · Cited by 228
p53-catalyzed annealing of complementary single-stranded nucleic acids.
Oberosler, P., Hloch, P., Ramsperger, U., & Stahl, H. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05893.x · Cited by 224
Bargonetti, J., Reynisdóttir, I., Friedman, P. N., & Prives, C. (1992) · Genes & Development · doi:10.1101/gad.6.10.1886 · Cited by 223
Dial 9-1-1 for p53: Mechanisms of p53 Activation by Cellular Stress
Ljungman, M. (2000) · Neoplasia · doi:10.1038/sj.neo.7900073 · Cited by 221
Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis
Desaintes, C. (1997) · The EMBO Journal · doi:10.1093/emboj/16.3.504 · Cited by 215
Interaction of p53 with the Human Rad51 Protein
Buchhop, S., Gibson, M. K., Wang, X. W., Wagner, P., Sturzbecher, H.-W., & Harris, C. C. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.19.3868 · Cited by 215
Histone acetyltransferase activity and interaction with ADA2 are critical for GCN5 function invivo
Candau, R. (1997) · The EMBO Journal · doi:10.1093/emboj/16.3.555 · Cited by 215
Essential role for p53-mediated transcription in E1A-induced apoptosis.
Sabbatini, P., Lin, J., Levine, A. J., & White, E. (1995) · Genes & Development · doi:10.1101/gad.9.17.2184 · Cited by 215
Overexpression of p53 and prognosis in breast cancer
Friedrichs, K., Gluba, S., Eidtmann, H., & Jonat, W. (1993) · Cancer · doi:10.1002/1097-0142(19931215)72:12<3593::aid-cncr2820721208>3.0.co;2-t · Cited by 211
Hinds, P. W., & Weinberg, R. A. (1994) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(94)90102-3 · Cited by 207
Picksley, S. M., & Lane, D. P. (1993) · BioEssays · doi:10.1002/bies.950151008 · Cited by 207
Metadata
- Authors
- Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., & Prives, C.
- Affiliations
- Columbia University (US)
- Venue
- Nature
- Published
- 1992-07
- Volume
- 358
- Issue
- 6381
- Pages
- 83-86
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2063158632
- Cited by
- 579
- References
- 29
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 8 · 2021: 5 · 2020: 8 · 2019: 3 · 2018: 4 · 2017: 1 · 2016: 4 · 2015: 1 · 2014: 6 · 2013: 5 · 2012: 7
- FWCI
- 38.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, transcriptional activation, wild-type p53, mutant p53, SV40 large T antigen, DNA-binding proteins, tumour suppressor, protein-protein interaction, transcriptional repression
- MeSH terms
- Animals, Antigens, Polyomavirus Transforming, DNA Mutational Analysis, DNA-Binding Proteins, Gene Expression Regulation, HeLa Cells, Humans, Neoplasm Proteins, Promoter Regions, Genetic, Structure-Activity Relationship, Transcription Factors, Transcription, Genetic, Tumor Suppressor Protein p53, Mice, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.